Revisiting p53 for cancer-specific chemo- and radiotherapy

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cell Cycle

• Publication date

  2014-02-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/cc.28108PMID 24526114PMCID PMC3979907
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation

  2013cited by this paper
• Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer

  2013cited by this paper
• p53-Based cyclotherapy: exploiting the ‘guardian of the genome' to protect normal cells from cytotoxic therapy

  2013cited by this paper
• A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo.

  2013cited by this paper
• Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity

  2013cited by this paper
• Cyclotherapy: opening a therapeutic window in cancer treatment.

  2012cited by this paper
• The hallmarks of cancer

  2012cited by this paper
• Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.

  2012cited by this paper
• Cyclotherapy: opening a therapeutic window in cancer treatment

  2012cited by this paper
• BRCA1-directed, enhanced and aberrant homologous recombination

  2012cited by this paper
• Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control

  2012cited by this paper
• p53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damage.

  2011cited by this paper
• Mutations in the BRCT binding site of BRCA1 result in hyper-recombination

  2011cited by this paper
• Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas

  2010cited by this paper
• Principles of cancer therapy: oncogene and non-oncogene addiction.

  2009cited by this paper
• Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion

  2009cited by this paper
• Exploiting synthetic lethal interactions for targeted cancer therapy

  2009cited by this paper
• Awakening guardian angels: drugging the p53 pathway

  2009cited by this paper
• p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.

  2007cited by this paper
• Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response.

  2007cited by this paper
• TAO kinases mediate activation of p38 in response to DNA damage

  2007cited by this paper
• Adenovirus p53 gene therapy

  2006cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• How Cancer Could be Cured by 2015

  2005cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• The Concept of Synthetic Lethality in the Context of Anticancer Therapy

  2005cited by this paper
• p53 protects from replication-associated DNA double-strand breaks in mammalian cells

  2004cited by this paper
• Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM

  2004cited by this paper
• DNA Damage Induces p53-dependent BRCA1 Nuclear Export*

  2004cited by this paper
• BLM helicase‐dependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination

  2003cited by this paper
• Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.

  2003cited by this paper
• Why did p53 gene therapy fail in ovarian cancer?

  2003cited by this paper
• Addiction to Oncogenes--the Achilles Heal of Cancer

  2002cited by this paper
• Mutant p53 proteins stimulate spontaneous and radiation-induced intrachromosomal homologous recombination independently of the alteration of the transactivation activity and of the G1 checkpoint

  1999cited by this paper
• Increase of spontaneous intrachromosomal homologous recombination in mammalian cells expressing a mutant p53 protein

  1997cited by this paper
• p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction.

  1996cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper

• Electrospun polycaprolactone/gelatin with pomegranate extract as a new concept for anticancer (liver, colon, breast).

  2025cites this paper
• The Cold Atmospheric Plasma Inhibits Cancer Proliferation Through Reducing Glutathione Synthesis

  2025cites this paper
• Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy

  2024cites this paper
• siRNA-based therapy for overcoming drug resistance in human solid tumours; molecular and immunological approaches.

  2024cites this paper
• Potential role of p53 deregulation in modulating immune responses in human malignancies: A paradigm to develop immunotherapy.

  2024cites this paper
• Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery Barriers

  2023cites this paper
• Next-Generation Sequencing Analysis of Mutations in Circulating Tumor DNA from the Plasma of Patients with Head–Neck Cancer Undergoing Chemo-Radiotherapy Using a Pan-Cancer Cell-Free Assay

  2023cites this paper
• Recent findings on the role of wild-type and mutant p53 in cancer development and therapy

  2022cites this paper
• Melatonin Modulation of Radiation-Induced Molecular Changes in MCF-7 Human Breast Cancer Cells

  2022cites this paper
• Kurarinone induced p53-Independent G0/G1 cell cycle arrest by degradation of K-RAS via WDR76 in human colorectal cancer cells.

  2022cites this paper
• Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities.

  2022cites this paper
• Cancer cell line for mechanisms of clinical anticancer drug resistance

  2021cites this paper
• The role of p53/p21/p16 in DNA damage signaling and DNA repair

  2021cites this paper
• Melatonin as a Radio-Sensitizer in Cancer

  2020cites this paper
• Exploring the p53 connection of cervical cancer pathogenesis involving north-east Indian patients

  2020cites this paper
• Modulation of apoptosis by melatonin for improving cancer treatment efficiency: An updated review.

  2019cites this paper
• PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway.

  2019cites this paper
• Targeting DNA repair in gliomas.

  2019cites this paper
• Insights of Crosstalk between p53 Protein and the MKK3/MKK6/p38 MAPK Signaling Pathway in Cancer

  2018cites this paper
• Evaluating the Remote Control of Programmed Cell Death, with or without a Compensatory Cell Proliferation

  2018cites this paper
• Genetic deficiency of the tumor suppressor protein p53 influences erythrocyte survival

  2018cites this paper
• The Molecular Pathology of Serous Endometrial Cancer

  2017cites this paper
• Precision Molecular Pathology of Uterine Cancer

  2017influential citation
• β2‐AR activation induces chemoresistance by modulating p53 acetylation through upregulating Sirt1 in cervical cancer cells

  2017cites this paper
• Molecular chess? Hallmarks of anti-cancer drug resistance

  2017influential citation
• Anticancer activity of seaweeds.

  2017cites this paper
• Screening candidate microRNA-mRNA regulatory pairs for predicting the response to chemoradiotherapy in rectal cancer by a bioinformatics approach

  2017cites this paper
• Induction of p53-Independent Apoptosis and G1 Cell Cycle Arrest by Fucoidan in HCT116 Human Colorectal Carcinoma Cells

  2017influential citation
• Radiosensitizing Glioma by Targeting ATM with Small Molecule Inhibitors

  2016cites this paper
• The Role of p53/p21/p16 in DNA-Damage Signaling and DNA Repair

  2016cites this paper
• Activation of insulin-like growth factor 1 receptor regulates the radiation-induced lung cancer cell apoptosis.

  2015cites this paper
• Histone deacetylase inhibitor suberoyl bis-hydroxamic acid suppresses cell proliferation and induces apoptosis in breast cancer cells.

  2015cites this paper
• Three-dimensional microenvironment confers enhanced sensitivity to doxorubicin by reducing p53-dependent induction of autophagy

  2015cites this paper
• Inhibition of P-TEFb by DRB suppresses SIRT1/CK2α pathway and enhances radiosensitivity of human cancer cells.

  2014cites this paper
• Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells

  2014cites this paper
• Anti-Cancer Therapies of 21st Century: Novel Approach to Treat Human Cancers Using Cold Atmospheric Plasma

  2014cites this paper
• DNA methylation protects cancer cells against non-canonical senescence

  year unknowncites this paper